WO2018180706A1 - 酸素供給装置及びその制御方法 - Google Patents
酸素供給装置及びその制御方法 Download PDFInfo
- Publication number
- WO2018180706A1 WO2018180706A1 PCT/JP2018/010818 JP2018010818W WO2018180706A1 WO 2018180706 A1 WO2018180706 A1 WO 2018180706A1 JP 2018010818 W JP2018010818 W JP 2018010818W WO 2018180706 A1 WO2018180706 A1 WO 2018180706A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oxygen
- user
- supply device
- sign
- value
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/021—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes operated by electrical means
- A61M16/022—Control means therefor
- A61M16/024—Control means therefor including calculation means, e.g. using a processor
- A61M16/026—Control means therefor including calculation means, e.g. using a processor specially adapted for predicting, e.g. for determining an information representative of a flow limitation during a ventilation cycle by using a root square technique or a regression analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/021—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes operated by electrical means
- A61M16/022—Control means therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
- A61B5/0816—Measuring devices for examining respiratory frequency
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0051—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes with alarm devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/1005—Preparation of respiratory gases or vapours with O2 features or with parameter measurement
- A61M16/101—Preparation of respiratory gases or vapours with O2 features or with parameter measurement using an oxygen concentrator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/0007—Special media to be introduced, removed or treated introduced into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0208—Oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/18—General characteristics of the apparatus with alarm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/202—Blood composition characteristics partial carbon oxide pressure, e.g. partial dioxide pressure (P-CO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/40—Respiratory characteristics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/40—Respiratory characteristics
- A61M2230/42—Rate
Definitions
- the present invention relates to an oxygen supply device used for oxygen therapy for inhaling high-concentration oxygen and a control method thereof.
- oxygen therapy as a treatment for chronic respiratory disease such as chronic obstructive pulmonary disease, pulmonary tuberculosis sequelae, chronic respiratory failure including pulmonary fibrosis, and heart failure and other various diseases such as hypoxemia.
- the oxygen therapy aims to improve and prevent hypoxemia by increasing the arterial oxygen partial pressure (PaO2) of a patient by administering a high concentration of oxygen gas.
- PaO2 arterial oxygen partial pressure
- Home oxygen therapy is a method in which a patient user operates an oxygen supply device according to a prescription of a medical staff such as a doctor and performs oxygen therapy at home.
- oxygen gas for inhalation is supplied from an oxygen supply device such as an oxygen concentrator or an oxygen cylinder as described in Patent Documents 1 and 2.
- an oxygen concentrator is used at home, and small and light oxygen cylinders are used for outings such as hospital visits and shopping. There are many.
- the flow rate of oxygen gas prescribed in home oxygen therapy is preferably prescribed according to the patient's condition such as rest, exertion, and sleep, in addition to the patient's disease and severity. For this reason, as in Patent Document 1, it has been studied to provide a sensor for measuring percutaneous arterial oxygen saturation (SpO2) in the oxygen supply device and set the flow rate of oxygen gas from the value of SpO2. In general, it is considered desirable to keep a patient's PaO2 value at 60 mmHg or more (SpO2 value is 90% or more).
- SpO2 value percutaneous arterial oxygen saturation
- Chronic respiratory failure is classified into type 1 respiratory failure without hypercarbonemia (arterial blood carbon dioxide partial pressure PaO2 ⁇ 45 mmHg) and type 2 respiratory failure with hypercarbonemia (arterial blood carbon dioxide partial pressure PaO2> 45 mmHg). being classified.
- the present invention includes the following aspects (1) to (12).
- An oxygen supply apparatus for supplying oxygen gas for inhalation to a user, the first sensor unit for acquiring information on the percutaneous arterial oxygen saturation (SpO2) of the user, and arterial blood dioxide of the user
- a second sensor unit that acquires vital information that fluctuates with an increase in the carbon partial pressure; and controls a supply amount of the oxygen gas supplied to the user, and based on the controlled supply amount
- a control unit for determining a risk of an abnormal increase in the arterial blood carbon dioxide partial pressure of the user, wherein the control unit has a value of the percutaneous arterial oxygen saturation equal to or higher than a first threshold value and the vital information.
- the vital information includes the number of breaths of the user, and the control unit determines that the value of the percutaneous arterial oxygen saturation (SpO2) is equal to or greater than a first threshold and the number of breaths When the value is equal to or greater than a second threshold, it is determined as the sign.
- the oxygen supply device is an oxygen concentration device that supplies, as the oxygen gas, a concentrated oxygen gas obtained by concentrating oxygen in the atmosphere.
- the oxygen supply device supplies high-pressure oxygen gas filled in a cylinder as the oxygen gas.
- any one of (1) to (4) when the control unit determines that the sign, the flow rate of the oxygen gas is controlled to zero or an initial set value. (6) In any one of (1) to (5), the control unit issues an alarm when it is determined as the sign. (7) In any one of (1) to (6), the first sensor unit is a pulse oximeter. (8) In any one of (1) to (7), the control unit controls the flow rate of the oxygen gas based on a value of the percutaneous arterial blood oxygen saturation (SpO2). .
- SpO2 percutaneous arterial blood oxygen saturation
- a method for controlling an oxygen supply apparatus that supplies oxygen gas for inhalation to a user the first step of acquiring percutaneous arterial blood oxygen saturation (SpO2) information of the user; A second step of acquiring vital information that fluctuates with an increase in the blood arterial blood carbon dioxide partial pressure, and a third step of determining a risk of an abnormal increase in the arterial blood carbon dioxide partial pressure of the user.
- SpO2 percutaneous arterial blood oxygen saturation
- the third step when the value of the percutaneous arterial blood oxygen saturation (SpO2) is not less than the first threshold and the vital information is out of a predetermined range, the arterial blood carbon dioxide partial pressure of the user is It is characterized as a sign of an abnormal rise in (10)
- the vital information includes the number of breaths of the user
- the value of the percutaneous arterial oxygen saturation (SpO2) is not less than a first threshold value and the breathing is performed.
- the value of the number of times is equal to or greater than a second threshold value, it is determined as the sign.
- (11) In (9) or (10) it is provided with a fourth step of controlling the flow rate of the oxygen gas to zero or a prescribed initial set value when it is determined as the sign in the third step. .
- a fifth step is provided in which an alarm is issued when the sign is determined in the third step.
- an oxygen supply apparatus and a control method thereof that can detect a sign of CO2 narcosis without directly measuring PaCO2.
- FIG. 6 is a diagram schematically showing the high carbon dioxide ventilation response of healthy subjects, type 1 respiratory failure patients and type 2 respiratory failure patients. It is a figure which shows the control flow in embodiment. It is a figure which shows the structure of an oxygen concentrator. It is a figure which shows a SpO2 feedback function.
- FIG. 1 is a diagram schematically showing the relationship between arterial blood carbon dioxide partial pressure (PaCO2) and the number of breaths per minute (BPM) for healthy subjects, type 1 respiratory failure patients and type 2 respiratory failure patients. It is.
- the solid line is the ventilatory response of a healthy person / type 1 respiratory failure patient, and the dotted line is the type 2 respiratory failure patient.
- the oxygen supply device of this embodiment measures the percutaneous arterial blood oxygen saturation (SpO2) of the user who receives home oxygen therapy with the oxygen supply device with the first sensor unit, and the number of breaths per minute of the user. (BPM) is measured by the second sensor unit.
- the abnormality determination determines that the user is highly likely to be in the state of B in FIG. 1 (a first sign of CO2 narcosis) when SpO2 is equal to or greater than a certain value, and the oxygen supply device Control.
- SpO2 is equal to or higher than a certain value and BPM decreases, it is determined that the user is likely to be in the state of C in FIG. 1 (second sign of CO2 narcosis), and the oxygen supply device You may control.
- the control flow of the oxygen supply device by the controller is shown in FIG.
- the oxygen supply device supplies oxygen gas having a high concentration (for example, an oxygen concentration of 90% or more) to the patient using a nasal cannula (step S1).
- the first sensor unit that measures the SpO2 value and the second sensor unit that measures the BPM measure the SpO2 value and the BPM value at predetermined intervals, respectively, and transmit them to the control unit (step S2).
- a pulse oximeter is preferably used for the first sensor unit for measuring the SpO2 value, and a known sensor can be used for the second sensor unit for measuring BPM as long as the number of breaths can be measured. .
- the control unit compares the measured SpO2 value with a preset first threshold value a (for example, 90%) (step S3). When the measured SpO2 value is lower than the first threshold value a, the process returns to step S2, and the SpO2 value and the BPM value are measured while continuing the supply of oxygen gas. If the SpO2 value is greater than or equal to the first threshold value a, the process proceeds to step S4 and the BPM value is checked.
- a for example, 90%
- the second threshold value b is set in advance for the BPM value. As shown in FIG. 1, the second threshold value b is set assuming a value when PaCO2 is high and BPM of a patient with type 2 respiratory failure increases. Generally, since the standard for a sudden change sign in a patient with type 2 respiratory failure is considered to be when the BPM exceeds about 30, the second threshold value b is set to BPM30, for example.
- the control unit compares the measured BPM value with a preset second threshold value b (step S4). When the BPM value is lower than the second threshold value b, the process returns to step S2, and the SpO2 value and the BPM value are measured while continuing the supply of oxygen gas. However, when the BPM value is equal to or greater than the second threshold value b, the control unit determines that the user is a sign of an abnormal increase in the arterial blood carbon dioxide partial pressure (step S5).
- the state in which the SpO2 value is equal to or higher than the first threshold value a and the BPM value is increased to be equal to or higher than the second threshold value b is insufficient in the discharge of carbon dioxide and stimulated by the increase in PaCO2 to increase BPM in FIG.
- the state of B that is, the first sign of CO2 narcosis may have occurred. Therefore, the control unit determines that it is a sign of abnormality (step S5), and immediately sets the flow rate of oxygen gas to zero (step S6).
- step S6 the flow rate is set to zero in step S6 and the supply of oxygen gas is stopped.
- the step after being determined as a sign of abnormality is not limited to this. For example, if an initial flow rate at which the CO2 narcosis is less likely to occur at a low flow rate is set in advance and it is determined in step S5 that there is an abnormality sign, in step S6, the control unit sets the oxygen gas flow rate to the initial flow rate, It is good also as control which continues supply of this. Furthermore, following step S6, a step in which the oxygen supply device issues an alarm may be provided.
- step S4 the upper limit of BPM is set as the second threshold value b, and the case where the upper limit is equal to or greater than the second threshold value b is determined as an abnormal sign.
- the control flow may proceed to step S5 and be determined as a sign of abnormality.
- a state where the BPM is equal to or lower than the third threshold value c is a decrease in the BPM corresponding to C in FIG.
- the third threshold value c that is the lower limit of the BPM can increase the certainty of the sign detection of the CO2 narcosis.
- a high flow rate of oxygen is administered to a patient in the acute phase, there may be a case where the state shown in FIG. In this embodiment, even in such a case, it is possible to catch an abnormal sign of the patient.
- FIG. 3 shows the configuration of an oxygen concentrator which is an embodiment of the oxygen supply device of the present invention.
- the oxygen concentrator is mainly used for home oxygen therapy.
- the oxygen concentrator is an apparatus that separates nitrogen contained in air and supplies high-concentration oxygen (oxygen-enriched gas) as oxygen gas for inhalation.
- a solid line connecting the components indicates a gas flow path, and a dotted line indicates a path of an electric signal such as a control signal.
- the oxygen supply apparatus in the present invention is not limited to the oxygen concentrator, and may be an oxygen supply apparatus that supplies high-pressure oxygen gas filled in a cylinder as oxygen gas for inhalation.
- the oxygen concentrator of the embodiment measures SpO2 of the user of the oxygen concentrator who receives home oxygen therapy with the pulse oximeter 2 that is the first sensor unit, and SpO2 is a set value prescribed by a doctor or the like (for example, 90% to 94%), the control unit 103 has a feedback function for controlling the oxygen gas flow rate.
- the SpO2 feedback function oxygen gas with a more suitable flow rate is supplied from the oxygen concentrator according to the user's state of rest, work, and sleep, thereby enhancing the effect of home oxygen therapy Can be expected.
- safety can be improved by detecting a sign of CO2 narcosis as described above.
- a main body 1 of the oxygen concentrator includes a compressor 102 that supplies pressurized air, an adsorption cylinder 107 that is filled with an adsorbent that selectively adsorbs nitrogen rather than oxygen, and a switching valve 105 that switches a sequence such as an adsorption process and a desorption process.
- a control valve 104 for increasing / decreasing the flow rate of the concentrated oxygen gas and a control unit 103 for controlling these are housed.
- the control unit 103 is constituted by a CPU (Central Processing Unit), for example.
- the flow rate of the oxygen gas concentrated in the main body 1 is adjusted by the control valve 104 and supplied to the user who receives home oxygen therapy by the cannula 4.
- the control unit 103 controls the control valve 104, for example, the flow rate of oxygen gas is controlled to a set value between 0.25 L / min and 5.00 L / min.
- the first sensor unit is a pulse oximeter 2, which is attached to a user's fingertip or the like and measures SpO 2 and transmits it to the control unit 103.
- the 2nd sensor part which acquires vital information which fluctuates accompanying a raise of a user's arterial blood carbon dioxide partial pressure is BPM sensor 3, and measures BPM of a user and transmits to control part 103.
- the raw material air is taken into the main body 1 from an air intake port provided with an intake filter 101 that removes foreign matters such as dust.
- the air usually contains about 21% oxygen gas, about 77% nitrogen gas, 0.8% argon gas, and 1.2% carbon dioxide and other gases.
- the oxygen concentrator concentrates and extracts only oxygen gas necessary as a breathing gas.
- the raw material air taken into the main body 1 is pressurized by the compressor 102 and sent to an adsorption cylinder 107 filled with an adsorbent made of zeolite or the like that selectively adsorbs nitrogen molecules.
- the control unit 103 operates the switching valve 105 to supply pressurized source air while sequentially switching the target adsorption cylinder 107, and about 77% nitrogen gas contained in the raw material air in the adsorption cylinder 107. Is selectively adsorbed and removed.
- the adsorbing cylinder 107 can use a known configuration such as a single cylinder type, a double cylinder type, or a multi-cylinder type of three or more cylinders.
- a two-cylinder or multi-cylinder adsorption cylinder 107 is preferably used.
- PSA type pressure fluctuation adsorption type
- the other adsorption cylinder B performs a desorption process to control the switching valve 105.
- the adsorption process and the desorption process are sequentially switched in opposite phases, and oxygen is continuously generated.
- a two-head type oscillating air compressor is used as a compressor having only a compression function or a compression / vacuum function, and a rotary air compression such as a screw type, a rotary type, a scroll type, etc.
- a machine may be used.
- the power source of the electric motor that drives the compressor 102 may be alternating current or direct current.
- nitrogen gas in the air is adsorbed by the adsorbent, and an oxygen-enriched gas mainly composed of oxygen that has not been adsorbed is taken out from the adsorption cylinder 107.
- the extracted oxygen-enriched gas flows into the product tank 106 and is stored through a check valve 108 provided so as not to flow back to the adsorption cylinder 107.
- the oxygen-enriched gas stored in the product tank 106 is a high-concentration oxygen gas such as 95%.
- control valve 104 is controlled to supply oxygen gas at a flow rate prescribed by a doctor or the like from the cannula 4 to the user.
- the oxygen concentration / flow rate sensor 110 feeds back the flow rate and oxygen concentration of the supplied oxygen gas to the control unit 103, and the generation and supply of oxygen gas by the oxygen concentrator is controlled.
- the SpO2 value and the BPM value are measured at a predetermined interval by the pulse oximeter 2 and the BPM sensor 3 to detect a sign of CO2 narcosis, and transmitted to the control unit 103.
- the control unit 103 determines a sign of abnormality according to the flow shown in FIG. 2, and controls the control valve 104 to stop the supply of oxygen gas when determining that there is a sign of CO2 narcosis.
- the compressor 102 and the switching valve 105 are controlled, and the production
- the control unit 103 issues an alarm to inform the user that the supply of oxygen gas has been stopped.
- the control unit 103 determines a sign of CO2 narcosis from the SpO2 value and the BPM value. Therefore, without providing a PaCO2 sensor in the oxygen concentrator, it is possible to predict the danger of CO2 narcosis and control the oxygen concentrator. When the control unit 103 of the oxygen concentrator determines a sign of CO2 narcosis, the safety of the user who receives home oxygen therapy can be further increased.
- the controller 103 determines that the SpO2 value measured by the pulse oximeter 2 is within a range prescribed by a medical worker such as a doctor (for example, 90% to 94%). ), The control valve 104 is controlled to adjust the oxygen gas flow rate.
- the user must operate the oxygen concentrator according to his / her own state and change the oxygen gas flow rate. There is a case. For example, as shown in FIG. 4A, when the user moves from resting to working, the amount of oxygen consumed increases and SpO2 decreases. For this reason, if the flow rate of oxygen gas is not changed from the prescription at rest to the prescription at work, the user feels uncomfortable such as shortness of breath.
- the control unit 103 controls the oxygen gas flow rate based on the SpO2 value measured by the pulse oximeter 2. For this reason, as shown in FIG. 4B, when the amount of oxygen transferred from the resting time to the working time is increased, the control unit 103 increases the flow rate of oxygen gas so that SpO2 does not decrease. Since the flow rate of oxygen gas is increased and SpO2 is kept constant, it is possible to prevent the user from feeling uncomfortable such as breathlessness. Since the oxygen concentrator adjusts and supplies the oxygen gas flow rate so that SpO2 is in the prescribed range, it can be expected to increase the effect of home oxygen therapy.
- the control unit 103 performs control according to the flow of FIG. 2 even while the SpO2 feedback function is in operation. With the SpO2 feedback function, the control unit 103 performs control to increase or decrease the flow rate of oxygen gas so that the range in which SpO2 is prescribed. Even if the flow rate of the oxygen gas increases, the control unit 103 monitors the sign of CO2 narcosis from the SpO2 value and the BPM value in the flow of FIG. 2 and stops the SpO2 feedback function if it is determined to be abnormal. Supply is stopped or switched to supply at an initial flow rate at which CO2 narcosis is less likely to occur at a low flow rate in advance. For this reason, the safety of the user who receives home oxygen therapy can be improved more.
- the oxygen supply device of the present invention can detect a sign of CO2 narcosis early, it is possible to further improve the safety of the user who receives home oxygen therapy by the oxygen concentrator.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Physiology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Oxygen, Ozone, And Oxides In General (AREA)
- Respiratory Apparatuses And Protective Means (AREA)
- Accommodation For Nursing Or Treatment Tables (AREA)
Abstract
Description
しかし、2型呼吸不全患者では、酸素療法を受けている患者の予後がよいとされており、CO2ナルコーシスリスクは酸素療法の禁忌理由にはならない。CO2ナルコーシスの危険性を十分考慮しながら慎重に酸素療法を行うことが望ましい。
(1)吸入用の酸素ガスを使用者に供給する酸素供給装置であって、使用者の経皮的動脈血酸素飽和度(SpO2)情報を取得する第1センサ部と、前記使用者の動脈血二酸化炭素分圧の上昇に付随して変動するバイタル情報を取得する第2センサ部と、前記使用者に供給する前記酸素ガスの供給量を制御し、かつ制御された前記供給量の基で、前記使用者の動脈血二酸化炭素分圧の異常な上昇の危険性を判断する制御部とを備え、前記制御部は、前記経皮的動脈血酸素飽和度の値が第1閾値以上で、かつ前記バイタル情報が予め定めた範囲を外れたとき、前記使用者の動脈血二酸化炭素分圧の異常な上昇の予兆と判断することを特徴とする。
(2)(1)において、前記バイタル情報は前記使用者の呼吸回数を含み、前記制御部は、前記経皮的動脈血酸素飽和度(SpO2)の値が第1閾値以上で、かつ前記呼吸回数の値が第2閾値以上であるとき、前記予兆と判断することを特徴とする。
(3)(1)又は(2)において、前記酸素供給装置は、大気中の酸素を濃縮した濃縮酸素ガスを前記酸素ガスとして供給する酸素濃縮装置であることを特徴とする。
(4)(1)又は(2)において、前記酸素供給装置は、ボンベに充填された高圧酸素ガスを前記酸素ガスとして供給することを特徴とする。
(5)(1)から(4)のいずれかにおいて、前記制御部は前記予兆と判断すると、前記酸素ガスの流量をゼロ又は初期設定値に制御することを特徴とする。
(6)(1)から(5)のいずれかにおいて、前記制御部は前記予兆と判断すると、警報を発することを特徴とする。
(7)(1)から(6)のいずれかにおいて、前記第1センサ部は、パルスオキシメータであることを特徴とする。
(8)(1)から(7)のいずれかにおいて、前記制御部は、前記経皮的動脈血酸素飽和度(SpO2)の値に基づいて、前記酸素ガスの流量を制御することを特徴とする。
(9)吸入用の酸素ガスを使用者に供給する酸素供給装置の制御方法であって、使用者の経皮的動脈血酸素飽和度(SpO2)情報を取得する第1ステップと、前記使用者の血中動脈血二酸化炭素分圧の上昇に付随して変動するバイタル情報を取得する第2ステップと、前記使用者の動脈血二酸化炭素分圧の異常な上昇の危険性を判断する第3ステップとを備え、前記第3ステップは、前記経皮的動脈血酸素飽和度(SpO2)の値が第1閾値以上で、かつ前記バイタル情報が予め定めた範囲を外れたとき、前記使用者の動脈血二酸化炭素分圧の異常な上昇の予兆と判断することを特徴とする。
(10)(9)において、前記バイタル情報は前記使用者の呼吸回数を含み、前記第3ステップは、前記経皮的動脈血酸素飽和度(SpO2)の値が第1閾値以上で、かつ前記呼吸回数の値が第2閾値以上であるとき、前記予兆と判断することを特徴とする。
(11)(9)又は(10)において、前記第3ステップで前記予兆と判断すると、前記酸素ガスの流量をゼロ又は処方された初期設定値に制御する第4ステップを備えることを特徴とする。
(12)(9)から(11)のいずれかにおいて、前記第3ステップで前記予兆と判断すると、警報を発する第5ステップを備えることを特徴とする。
呼吸数に関していえば、換気ドライブが正常な健常者や1型呼吸不全患者と、2型呼吸不全患者の二酸化炭素換気応答は多くの場合、図1に示すようになる。図1は健常者・1型呼吸不全患者と2型呼吸不全患者について、動脈血二酸化炭素分圧(PaCO2)と、1分間当たりの呼吸回数(breath per minutes:BPM)の関係を模式的に示す図である。実線は健常者・1型呼吸不全患者、点線は2型呼吸不全患者の換気応答である。
なお上記の通り、PaCO2値の上昇に伴い、図1のBの状態を経てCの状態に移行するケースもあるが、急性期の患者に対し高流量の酸素を投与した場合などは一気に図1のCの状態に至るケースも考えられる。本実施形態では、そのようなケースでも患者の異常兆候をとらえることが可能となっている。
2 パルスオキシメータ(第1センサ部)
3 BPMセンサ(第2センサ部)
4 カニューラ
101 吸気フィルタ
102 コンプレッサ
103 制御部
104 コントロールバルブ
105 切替弁
106 製品タンク
107 吸着筒
108 逆止弁
109 調圧弁
110 酸素濃度/流量センサ
Claims (12)
- 吸入用の酸素ガスを使用者に供給する酸素供給装置であって、
使用者の経皮的動脈血酸素飽和度(SpO2)情報を取得する第1センサ部と、
前記使用者の血中二酸化炭素濃度の上昇に付随して変動するバイタル情報を取得する第2センサ部と、
前記使用者に供給する前記酸素ガスの供給量を制御し、かつ制御された前記供給量の基で、前記使用者の動脈血二酸化炭素分圧の異常な上昇の危険性を判断する制御部とを備え、
前記制御部は、前記経皮的動脈血酸素飽和度の値が第1閾値以上で、かつ前記バイタル情報が予め定めた範囲を外れたとき、前記使用者の動脈血二酸化炭素分圧の異常な上昇の予兆と判断することを特徴とする酸素供給装置。 - 前記バイタル情報は前記使用者の呼吸回数を含み、
前記制御部は、前記経皮的動脈血酸素飽和度(SpO2)の値が第1閾値以上で、かつ前記呼吸回数の値が第2閾値以上であるとき、前記予兆と判断することを特徴とする請求項1に記載の酸素供給装置。 - 前記酸素供給装置は、大気中の酸素を濃縮した濃縮酸素ガスを前記酸素ガスとして供給する酸素濃縮装置であることを特徴とする請求項1又は2に記載の酸素供給装置。
- 前記酸素供給装置は、ボンベに充填された高圧酸素ガスを前記酸素ガスとして供給することを特徴とする請求項1又は2に記載の酸素供給装置。
- 前記制御部は前記予兆と判断すると、前記酸素ガスの流量をゼロ又は初期設定値に制御することを特徴とする請求項1から4のいずれか1項に記載の酸素供給装置。
- 前記制御部は前記予兆と判断すると、警報を発することを特徴とする請求項1から5のいずれか1項に記載の酸素供給装置。
- 前記第1センサ部は、パルスオキシメータであることを特徴とする請求項1から6のいずれか1項に記載の酸素供給装置。
- 前記制御部は、前記経皮的動脈血酸素飽和度(SpO2)の値に基づいて、前記酸素ガスの流量を制御することを特徴とする請求項1から7のいずれか1項に記載の酸素供給装置。
- 吸入用の酸素ガスを使用者に供給する酸素供給装置の制御方法であって、
使用者の経皮的動脈血酸素飽和度(SpO2)情報を取得する第1ステップと、
前記使用者の動脈血二酸化炭素分圧の上昇に付随して変動するバイタル情報を取得する第2ステップと、
前記使用者の動脈血二酸化炭素分圧の異常な上昇の危険性を判断する第3ステップとを備え、
前記第3ステップは、前記経皮的動脈血酸素飽和度(SpO2)の値が第1閾値以上で、かつ前記バイタル情報が予め定めた範囲を外れたとき、前記使用者の動脈血二酸化炭素分圧の異常な上昇の予兆と判断することを特徴とする酸素供給装置の制御方法。 - 前記バイタル情報は前記使用者の呼吸回数を含み、
前記第3ステップは、前記経皮的動脈血酸素飽和度(SpO2)の値が第1閾値以上で、かつ前記呼吸回数の値が第2閾値以上であるとき、前記予兆と判断することを特徴とする請求項9に記載の酸素供給装置の制御方法。 - 前記第3ステップで前記予兆と判断すると、前記酸素ガスの流量をゼロ又は処方された初期設定値に制御する第4ステップを備えることを特徴とする請求項9又は10に記載の酸素供給装置の制御方法。
- 前記第3ステップで前記予兆と判断すると、警報を発する第5ステップを備えることを特徴とする請求項9から11のいずれか1項に記載の酸素供給装置の制御方法。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201880022213.0A CN110461396B (zh) | 2017-03-31 | 2018-03-19 | 供氧装置及其控制方法 |
EP18775445.2A EP3603711A4 (en) | 2017-03-31 | 2018-03-19 | OXYGEN SUPPLY DEVICE AND METHOD FOR CONTROLLING THE SAME |
KR1020197029633A KR102590638B1 (ko) | 2017-03-31 | 2018-03-19 | 산소 공급 장치 및 그 제어 방법 |
JP2019509349A JP6891266B2 (ja) | 2017-03-31 | 2018-03-19 | 酸素供給装置及びその制御方法 |
US16/498,627 US20200094007A1 (en) | 2017-03-31 | 2018-03-19 | Oxygen supply device and method for controlling same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017069845 | 2017-03-31 | ||
JP2017-069845 | 2017-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018180706A1 true WO2018180706A1 (ja) | 2018-10-04 |
Family
ID=63677336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/010818 WO2018180706A1 (ja) | 2017-03-31 | 2018-03-19 | 酸素供給装置及びその制御方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20200094007A1 (ja) |
EP (1) | EP3603711A4 (ja) |
JP (1) | JP6891266B2 (ja) |
KR (1) | KR102590638B1 (ja) |
CN (1) | CN110461396B (ja) |
WO (1) | WO2018180706A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111991662A (zh) * | 2020-09-14 | 2020-11-27 | 江西安联医疗器械有限公司 | 一种自动提供氧气治疗方案的智能*** |
CN115512780A (zh) * | 2022-11-23 | 2022-12-23 | 山东未来网络研究院(紫金山实验室工业互联网创新应用基地) | 一种PaCO2实时预警模型建立方法及*** |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102420844B1 (ko) | 2020-09-22 | 2022-07-14 | (재)예수병원유지재단 | 경피적 산소 분압 측정장치용 감지장치 |
CN112346488B (zh) * | 2020-11-06 | 2024-01-30 | 西藏大学 | 一种高原弥散式供氧控制方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001309981A (ja) | 2000-04-28 | 2001-11-06 | Sanyo Electric Co Ltd | 医療用酸素濃縮器 |
JP2003062075A (ja) * | 2001-08-27 | 2003-03-04 | Yazaki Corp | 医療用ガス供給監視システム |
JP2003126256A (ja) * | 2001-10-24 | 2003-05-07 | Yazaki Corp | 緊急警報機能付き搬送用酸素吸引器 |
JP2008067941A (ja) * | 2006-09-14 | 2008-03-27 | Imagineering Kk | 酸素供給装置 |
JP2013208217A (ja) * | 2012-03-30 | 2013-10-10 | Fukuda Denshi Co Ltd | 生体情報表示装置 |
US20140007870A1 (en) * | 2011-03-24 | 2014-01-09 | Oskar Frånberg | Device and method for supplying and dosing gas to a breathing person |
JP2014064772A (ja) | 2012-09-26 | 2014-04-17 | Teijin Pharma Ltd | 酸素濃縮装置 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080295839A1 (en) * | 2007-06-01 | 2008-12-04 | Habashi Nader M | Ventilator Apparatus and System of Ventilation |
EP2948059B1 (en) * | 2013-06-13 | 2017-02-15 | Koninklijke Philips N.V. | Device and method for determining a partial carbon dioxide pressure in a subject of interest |
US10869987B2 (en) * | 2013-12-20 | 2020-12-22 | B/E Aerospace, Inc | Pulse saturation oxygen delivery system and method |
US9867553B2 (en) * | 2014-07-17 | 2018-01-16 | Christian I. Garaycochea | Attachable nasal cannula |
US20160058346A1 (en) * | 2014-09-02 | 2016-03-03 | General Electric Company | Determination of arterial co2 partial pressure |
US20160095994A1 (en) * | 2014-10-01 | 2016-04-07 | Third Wind, Llc | Hypoxic Breathing Apparatus and Method |
CN110520043B (zh) * | 2016-12-05 | 2023-04-21 | 梅迪平斯公司 | 使用呼吸气体样品进行呼吸测量的***和方法 |
-
2018
- 2018-03-19 EP EP18775445.2A patent/EP3603711A4/en active Pending
- 2018-03-19 WO PCT/JP2018/010818 patent/WO2018180706A1/ja active Application Filing
- 2018-03-19 US US16/498,627 patent/US20200094007A1/en active Pending
- 2018-03-19 JP JP2019509349A patent/JP6891266B2/ja active Active
- 2018-03-19 CN CN201880022213.0A patent/CN110461396B/zh active Active
- 2018-03-19 KR KR1020197029633A patent/KR102590638B1/ko active IP Right Grant
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001309981A (ja) | 2000-04-28 | 2001-11-06 | Sanyo Electric Co Ltd | 医療用酸素濃縮器 |
JP2003062075A (ja) * | 2001-08-27 | 2003-03-04 | Yazaki Corp | 医療用ガス供給監視システム |
JP2003126256A (ja) * | 2001-10-24 | 2003-05-07 | Yazaki Corp | 緊急警報機能付き搬送用酸素吸引器 |
JP2008067941A (ja) * | 2006-09-14 | 2008-03-27 | Imagineering Kk | 酸素供給装置 |
US20140007870A1 (en) * | 2011-03-24 | 2014-01-09 | Oskar Frånberg | Device and method for supplying and dosing gas to a breathing person |
JP2013208217A (ja) * | 2012-03-30 | 2013-10-10 | Fukuda Denshi Co Ltd | 生体情報表示装置 |
JP2014064772A (ja) | 2012-09-26 | 2014-04-17 | Teijin Pharma Ltd | 酸素濃縮装置 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111991662A (zh) * | 2020-09-14 | 2020-11-27 | 江西安联医疗器械有限公司 | 一种自动提供氧气治疗方案的智能*** |
CN111991662B (zh) * | 2020-09-14 | 2023-08-15 | 江西安联医疗器械有限公司 | 一种自动提供氧气治疗方案的智能*** |
CN115512780A (zh) * | 2022-11-23 | 2022-12-23 | 山东未来网络研究院(紫金山实验室工业互联网创新应用基地) | 一种PaCO2实时预警模型建立方法及*** |
Also Published As
Publication number | Publication date |
---|---|
KR102590638B1 (ko) | 2023-10-17 |
US20200094007A1 (en) | 2020-03-26 |
CN110461396B (zh) | 2022-11-01 |
EP3603711A4 (en) | 2020-03-25 |
EP3603711A1 (en) | 2020-02-05 |
CN110461396A (zh) | 2019-11-15 |
JPWO2018180706A1 (ja) | 2019-11-07 |
KR20190130596A (ko) | 2019-11-22 |
JP6891266B2 (ja) | 2021-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6891266B2 (ja) | 酸素供給装置及びその制御方法 | |
EP3365052B1 (en) | Connection of a spontaneous delivery device to a concentrator | |
JP6821012B2 (ja) | 酸素供給装置及びその制御方法 | |
US20080202525A1 (en) | Setting mandatory mechanical ventilation parameters based on patient physiology | |
KR102540426B1 (ko) | 산소 요법 시스템 | |
US20140261424A1 (en) | Methods and systems for phase shifted pressure ventilation | |
JP2002085568A (ja) | 酸素供給装置及びその制御装置並びに記録媒体 | |
CA2623052A1 (en) | System and method of administering a pharmaceutical gas to a patient | |
US20150068528A1 (en) | Continuous positive airway pressure therapy target pressure comfort signature | |
CN113490523B (zh) | 呼吸支持设备及其控制方法和存储介质 | |
JP4594112B2 (ja) | 酸素濃縮装置およびその制御方法 | |
CN107296737B (zh) | 一种呼吸机 | |
JP2004298554A (ja) | 呼吸用気体供給装置 | |
JP2001314507A (ja) | 医療用酸素濃縮装置 | |
JP6109507B2 (ja) | 酸素供給装置 | |
JP2023533598A (ja) | 流れで起動するガス供給 | |
JP2019162337A (ja) | 酸素濃縮装置およびその制御方法 | |
JP4308678B2 (ja) | 酸素供給装置 | |
JP4606655B2 (ja) | 呼吸用気体供給装置 | |
JP2005040422A (ja) | 人工呼吸補助装置 | |
JP5907675B2 (ja) | 一酸化炭素投与システム | |
WO2020181279A1 (en) | Respiratory support device and method of providing hypoxemia relief |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18775445 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019509349 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20197029633 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018775445 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2018775445 Country of ref document: EP Effective date: 20191031 |